Obesity drugs show early promise against PMOS

Key Points:

• Charlotte Touzalin and her mother Anne Schultz were diagnosed with polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8 women worldwide, after years of unexplained symptoms like weight gain, abnormal periods, and unwanted facial hair.
• PMOS involves insulin resistance and elevated testosterone, leading to symptoms such as irregular periods, acne, and hair growth; it often runs in families and lacks a definitive cause or specific treatment beyond symptom management.
• Touzalin participated in a study using GLP-1 drugs, such as semaglutide, which showed promising results including significant weight loss, hormone balance improvement, and normalized periods, offering new hope for PMOS treatment.
• Despite positive outcomes, insurance coverage for GLP-1 drugs remains a barrier as these medications are not officially approved for PMOS, causing many patients to struggle to access them outside of clinical trials.
• Researchers and doctors continue to study GLP-1 drugs for PMOS, with some prescribing them off-label; however, results vary and side effects exist, highlighting the need for further research and better treatment access.